Trade Name(s)

  • Steglatro

Ther. Class.

Pharm. Class.
sodium-glucose co-transporter 2 (SGLT2) inhibitors


Adjunct to diet and exercise in the management of type 2 diabetes mellitus.


Inhibits proximal renal tubular sodium-glucose co-transporter 2 (SGLT2), which reduces reabsorption of glucose and lowers renal threshold for glucose, and ultimately increases excretion of glucose in urine.

Therapeutic Effect(s):

Improved glycemic control.


Absorption: Completely absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Metabolism and Excretion: Mostly metabolized by UDP-glucuronyl transferases (UGT) to inactive metabolites; minimal metabolism by CYP isoenzymes (12%). 41% excreted in feces (33.8% as unchanged drug), 50.2% excreted in urine (1.5% as unchanged drug).

Half-life: 16.6 hr.

TIME/ACTION PROFILE (plasma levels)

POunknown1 hr24 hr


Contraindicated in:

  • Hypersensitivity;
  • Severe renal impairment (eGFR <30 mL/min/1.73 m2 ), end-stage renal disease or on dialysis;
  • Type 1 diabetes;
  • Diabetic ketoacidosis;
  • Severe hepatic impairment;
  • OB:  Avoid use during second and third trimesters (↑ risk of renal impairment in fetus);
  • Lactation: Avoid use during breast feeding.

Use Cautiously in:

  • Moderate renal impairment (eGFR 30–59 mL/min/1.73 m2  (↑ risk of adverse reactions related to ↓ intravascular volume) (use not recommended);
  • Renal impairment (eGFR <60 mL/min/1.73 m2 ), age ≥65 yr, low systolic BP, or concurrent use of diuretics (↑ risk of hypotension);
  • Acute febrile illness, reduced caloric intake due to illness or surgery, history of pancreatitis or pancreatic surgery, or alcohol abuse (↑ risk of ketoacidosis);
  • Hypovolemia, chronic kidney disease, HF, or concurrent use of diuretics, NSAIDs, ACE inhibitors, or ARBs (↑ risk of acute kidney injury);
  • Previous amputation, peripheral vascular disease, neuropathy, or diabetic foot infection (↑ risk of lower limb amputation);
  • History of genital mycotic infections or uncircumcised (↑ risk of genital mycotic infections);
  • Geri:  ↑ risk of adverse reactions related to ↓ intravascular volume;
  • OB:  Use during first trimester only if potential maternal benefit justifies potential fetal risk;
  • Pedi:  Safety and effectiveness not established.

Adverse Reactions/Side Effects

CNS: dizziness, headache, syncope

CV: hypotension

Endo: hypoglycemia (↑ with other medications)

F and E: KETOACIDOSIS, dehydration, polydipsia

GU: UROSEPSIS, genital mycotic infection, acute kidney injury, polyuria, urinary tract infection (including pyelonephritis), vaginal pruritus

Metabolic: ↓ weight, hyperlipidemia

MS: back pain, lower limb amputation (primarily toe)


* CAPITALS indicate life-threatening.
Underline indicate most frequent.



  • ↑ risk of hypoglycemia with  insulin  or  insulin secretagogues ; dose adjustments may be required.
  • Concurrent use with NSAIDs, diuretics, ACE inhibitors, or  angiotensin receptor blockers  may ↑ risk of acute kidney injury.


PO (Adults):  eGFR ≥ 60 mL/min/1.73 m2 – 5 mg once daily initially; may ↑ to 15 mg once daily if needed.


Tablets: 5 mg, 15 mg


  • Observe patient for signs and symptoms of hypoglycemic reactions (abdominal pain, sweating, hunger, weakness, dizziness, headache, tremor, tachycardia, anxiety).
  • Monitor for signs and symptoms of volume depletion (dizziness, feeling faint, weakness, orthostatic hypotension) after initiating therapy.
  • Monitor for signs and symptoms of ketoacidosis (nausea, vomiting, abdominal pain, generalized malaise, shortness of breath). Treat clinically and discontinue ertugliflozin if ketoacidosis occurs.
  • Monitor for urinary tract infection, new pain, pain on urination, fever, flank pain, tenderness, sores, or ulcers involving lower limbs; discontinue ertugliflozin if these occur.
  • Monitor for signs and symptoms of necrotizing fasciitis of the perineum (pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise). If suspected, discontinue ertugliflozin, monitor blood glucose levels, and provide alternative therapy for glycemic control. Start treatment immediately with broad-spectrum antibiotics. May require surgical debridement.

Lab Test Considerations: Monitor hemoglobin A1C prior to and periodically during therapy.

  • May cause ↑ uric acid levels.
  • Assess renal function prior to and periodically during therapy. May ↑ serum creatinine and ↓ eGFR. Monitor renal function, especially in patients with eGFR <60 mL/min/1.73 m2 .
  • May cause ↑ serum phosphate levels.
  • May cause ↑ LDL-C. Monitor serum lipid levels periodically during therapy.
  • Causes positive test for urine glucose.

Potential Diagnoses


  • Correct volume depletion before starting ertugliflozin.
  • Patients stabilized on a diabetic regimen who are exposed to stress, fever, trauma, infection, or surgery may require administration of insulin.
  • Correct volume depletion prior to beginning therapy with ertugliflozin.
  • PO Administer in morning with or without food.

Patient/Family Teaching

  • Instruct patient to take ertugliflozin as directed. Take missed doses as soon as remembered, unless it is almost time for next dose; do not double doses. Advise patient to read the  Medication Guide before starting and with each Rx refill in case of changes.
  • Explain to patient that ertugliflozin helps control hyperglycemia but does not cure diabetes. Therapy is usually long term.
  • Instruct patient not to share this medication with others, even if they have the same symptoms; it may harm them.
  • Encourage patient to follow prescribed diet, medication, and exercise regimen to prevent hyperglycemic or hypoglycemic episodes.
  • Review signs of hypoglycemia and hyperglycemia with patient. If hypoglycemia occurs, advise patient to take a glass of orange juice or 2–3 tsp of sugar, honey, or corn syrup dissolved in water, and notify health care professional.
  • Instruct patient in proper testing of blood glucose and urine ketones. Inform patient that ertugliflozin will cause a positive test result when testing for urine glucose. Advise patient to monitor ketones, even if blood glucose is not elevated and blood glucose during periods of stress or illness. Notify health care professional if signs and symptoms of ketoses or significant changes occur.
  • Inform patient that ertugliflozin may cause yeast infections. Women may have signs and symptoms of a vaginal yeast infection (vaginal odor, white or yellow vaginal discharge [may be lumpy or look like cottage cheese], vaginal itching). Men may have signs and symptoms of a yeast infection of the penis (redness, itching, or swelling of penis; rash on penis; foul smelling discharge from penis; pain in skin around penis). Advise patient to notify health care professional if yeast infection occurs.
  • Advise patient to notify health care professional promptly if rash; hives; or swelling of face, lips, or throat occur.
  • Advise patient to notify health care professional if signs and symptoms of urinary tract infections (painful urination, flank pain, fever), hypotension, or perineal necrotizing fasciitis (pain or tenderness, redness, or swelling of genitals or area from genitals back to the rectum, with a fever above 100.4°F; malaise) occur.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications, especially other oral hypoglycemic medications.
  • Advise patient to notify health care professional if pregnancy is planned or suspected and to avoid breast feeding during therapy.

Evaluation/Desired Outcomes

Improved hemoglobin A1C and glycemic control in adults with Type 2 diabetes.

ertugliflozin is a sample topic from the Davis's Drug Guide.

To view other topics, please or .

Nursing Central is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. .